Stopping Treatment in CML and dose reduction in clinical practice: Can we do it safely? YES WE CAN!

Similar documents
The concept of TFR (Treatment Free Remission) in CML

Oxford Style Debate on STOPPING Treatment.

Treatment free remission in CML: from the concept to practice. François-Xavier Mahon. Cancer Center Bordeaux Université Bordeaux, France

Stopping treatment how much we understand about mechanisms to stop successfully today, and where are the limits? Andreas Hochhaus

Starting & stopping therapy in Chronic Myeloid Leukemia: What more is needed? Richard A. Larson, MD University of Chicago March 2019

La terapia della LMC: è possibile guarire senza trapianto? Fabrizio Pane

IRIS 8-Year Update. Management of TKI Resistance Will KD mutations matter? Sustained CCyR on study. 37% Unacceptable Outcome 17% 53% 15%

Low doses of tyrosine kinase inhibitors in CML

Chronic Myeloid Leukaemia

Treatment free remission 2016

HOW I TREAT CML. 4. KONGRES HEMATOLOGOV IN TRANSFUZIOLOGOV SLOVENIJE Z MEDNARODNO UDELEŽBO Terme Olimia, Podčetrtek,

I nuovi guariti? La malattia minima residua nella leucemia mieloide cronica. Fabrizio Pane

CML: Living with a Chronic Disease

ELN Recommendations on treatment choice and response. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy

CML and Future Perspective. Hani Al-Hashmi, MD

Guidelines and real World: Management of CML in chronic and advanced phases. Carolina Pavlovsky. FUNDALEU May 2017 Frankfurt

History of CML Treatment

Dati sulla sospensione della terapia

Role of Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed CML. GIUSEPPE SAGLIO, MD University of Torino, Italy

The BCR-ABL1 fusion. Epidemiology. At the center of advances in hematology and molecular medicine

Deep molecular responses for treatment- free remission in chronic myeloid leukemia

Imatinib dose intensification, combination therapies. Andreas Hochhaus Universitätsklinikum Jena, Germany

Stopping TKI s in CML- Are we There Yet? Joseph O. Moore, MD Duke Cancer Institute

CML: Yesterday, Today and Tomorrow. Jorge Cortes, MD Chief CML Section Department of Leukemia The University of Texas, M.D. Anderson Cancer Center

When to change therapy? Andreas Hochhaus Universitätsklinikum Jena, Germany

What is New in CML Jorge Cortes, MD Chief, CML and AML Sections Department of Leukemia MD Anderson Cancer Center Houston, Texas

Imatinib & Ponatinib. Two ends of the spectrum in 2016s reality

Milestones and Monitoring

2 nd Generation TKI Frontline Therapy in CML

EUROPEAN LEUKEMIANET RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA

CML David L Porter, MD University of Pennsylvania Medical Center Abramson Cancer Center CML Current treatment options for CML

Hull and East Yorkshire and North Lincolnshire NHS Trusts Haematology Multidisciplinary Team Guideline and Pathway. Chronic Myeloid Leukaemia

DAVID S. SNYDER, M.D.

Patient With Chronic Myeloid Leukemia in Complete Cytogenetic Response: What Does It Mean, and What Does One Do Next?

Juan Luis Steegmann Hospital de la Princesa. Madrid. JL Steegmann

10 YEARS EXPERIENCE OF TYROSINE KINASE INHIBITOR THERAPY FOR CML IN OXFORD

1794 Updating Long-Term Outcome of Intermittent Imatinib. (INTERIM) Treatment in Elderly Patients with Ph+-CML

Does Generic Imatinib Change the Treatment Approach in CML?

Chronic Myeloid Leukemia A Disease of Young at Heart but Not of Body

IS MUTATION ANALYSIS OF BCR-ABL OF ANY VALUE IN CLINICAL MANAGEMENT OF CML PATIENTS? David Marin, Imperial College London

Philadelphia Positive (Ph+) Chronic Myeloid Leukaemia

EVI-1 oncogene expression predicts survival in chronic phase CML patients resistant to imatinib

MRD in CML (BCR-ABL1)

CML: Role of combination treatments, Interferon and immunotherapy in CML

2nd generation TKIs to first line therapy

HSCT for Myeloproliferative Disorders. Jane Apperley

CML UPDATE 2018 DAVID S. SNYDER, M.D. MARCH

SESSION III: Chronic myeloid leukemia PONATINIB. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy

ESMO Updated Guidelines & Treatment Strategies in CML-CP: Maximizing Eligibility for TFR.

Discontinuation of Imatinib in Patients with Chronic Myeloid Leukemia Who Have Maintained Complete Molecular Response: Update Results of the STIM

Contemporary and Future Approaches in CML. Emory Meeting; Sea Island August 2014 Hagop Kantarjian, M.D.

1 Educational session salient points. Tim Hughes, Vivian Oehler and Rick Van Etten. Tim - Imatinib is a less toxic drug than what we are seeing with

NEW DRUGS IN HEMATOLOGY

Accepted Manuscript. Improving Outcomes in Chronic Myeloid Leukemia Over Time in the Era of Tyrosine Kinase Inhibitors. Pradnya Chopade, Luke P.

Welcome & Introductions

Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: What s Stopping us from Stopping?

15 th Annual Miami Cancer Meeting

Molecular monitoring of CML patients

What is New in CML in Hagop Kantarjian, M.D. February 2011

Post ASH Actualités LMC

Management of CML in blast crisis. Lymphoma Tumor Board November 27, 2015

Study Design and Endpoints

Recent advances in the path toward the cure for chronic myeloid leukemia

RESEARCH ARTICLE. Introduction. Methods Wiley Periodicals, Inc.

Outlook CML 2016: What is being done on the way to cure

BMS Satellite Symposium

Current Monitoring for CML: Goals and. Jorge Cortes, MD Chief, CML & AML Section Department of Leukemia MD Anderson Cancer Center

Diagnosis and Management of Chronic Myeloid Leukaemia

Venice Meeting Highlights: Key lessons. Conclusions Michele Baccarani Rüdiger Hehlmann

Understanding Treatment-Free Remission and How It Impacts You

517 Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML

Welcome and Introductions

New drugs and trials. Andreas Hochhaus

How I treat high risck CML

Highlights in myeloproliferative neoplasms

CML Update 2016 Arthur 2016

Updated review of nilotinib as frontline treatment for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia

The current standard of care in CML. Gianantonio Rosti, MD University of Bologna Bologna, Italy

A 34-year old women came because of abdominal discomfort. Vital sign was stable. Spleen tip was palpable.

Contemporary and Future Approaches in Management of CML. Disclosures

New drugs in first-line therapy

Institute of Translational Medicine, University of Liverpool, Liverpool, UK 2

Blast Phase Chronic Myelogenous Leukemia

Articles. Funding Newcastle University and Bloodwise.

Molecular Detection of BCR/ABL1 for the Diagnosis and Monitoring of CML

Supplementary Online Content

Chronic myeloid leukemia (CML) Warunsuda Sripakdee, BCOP,BCP Prince of Songkla University

9/26/2018. Learning Objectives

NCCP Chemotherapy Protocol. Bosutinib Monotherapy

Dose reduction. What do we know and how we do it in clinical practice. Andreas Hochhaus

New Anti Leukemic treatments deserve a Cardioncology approach. Guido Gini AOU «Ospedali Riuniti» Università Politecnica delle Marche Ancona

Goals for chronic myeloid leukemia TK inhibitor treatment: how little disease is too much?

CML 301 SOME INTRODUCTION INTO CML, CML SCIENCE, DRUG DEVELOPMENT AND INFORMATION RESOURCES. by Sarunas Narbutas Jan Geissler.

Second Tyrosine Kinase Inhibitor Discontinuation Attempt in Patients With Chronic Myeloid Leukemia

CML EHA: what s new? Novità dall EHA >> [ Leucemia mieloide cronica ] Relatore: G. MARTINELLI. Borgo S. Luigi Monteriggioni (Siena) ottobre 2008

CML: definition. CML epidemiology. CML diagnosis. CML: peripheralbloodsmear. Cytogenetic abnormality of CML

Allogeneic SCT for. 1st TKI. Vienna Austria. Dr. Eduardo Olavarría Complejo Hospitalario de Navarra

Time slots Sessions Location December 5 th (Friday) Friday Scientific Workshop on Myeloid Development

Molecular monitoring in CML and the prospects for treatment-free remissions

Analytical and economic evaluation of the fully automated Xpert BCR-ABL assay from Cepheid

Transcription:

Stopping Treatment in CML and dose reduction in clinical practice: Can we do it safely? YES WE CAN! Dragana Milojković The Hammersmith Hospital, London, UK

Leukemic burden Current Aim of TKI therapy Molecular response Lifelong maintenance? CP-CML at Diagnosis PFS EFS Near-normal life expectancy <10% <1% <0.1% <0.1% Stable or improving MMR M3 M6 M12 M18 > M18 Treatment change upon lack or loss of an optimal response, progression or unacceptable side effects Baccarani et al. JCO 2009; 27: 6041-6051 Björkholm et al. JCO 2011: 2514-2420 Gambacorti-Passerini et al. JNCI 2011; 103: 553-561 Time on TKI therapy

Current Aim of TKI therapy But... Lifelong maintenance????

Reasons to discontinue TKI therapy Mandatory TKI interruption or discontinuation Other considerations in the optimal responder Pregnancy Severe side-effects Concomitant disease Low-grade side-effects affecting QoL Potential unknown future complications The need to take daily therapy Cost of therapy > 2000 patients discontinued TKI in clinical trials world-wide Ann Haematol 2015 Apr;94 Suppl 2:S187-93

Patient Perception of Desirability of Stopping is Related to Risk of Relapse Sanford et al, Current Oncology, 2014

Survival without molecular relapse STIM: Stopping imatinib is feasible 7/2007-12/2009 CP-CML, n=100 Imatinib 3 years Undetectable BCR-ABL 2 years 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 0.0 0 Molecular relapses: n=61/100 Majority (n=58) <7/12 3 late relapses at month 19, 20 and 22 Survival without molecular relapse: 39% (95% CI: 29-48) at 24 and 36 months (MRFS) 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51 54 57 60... Months since discontinuation of imatinib Undetectable BCR-ABL: at least 50 000 copies of the ABL control gene Molecular relapse: defined by 2 positive RQ-PCR results over 1 month showing a significant rise in BCR-ABL transcripts; triggers imatinib resumption. RT-qPCR monthly for 1 year 2 monthly for year 2 3 monthly thereafter stable MR4.5 in 40% of all CML patients after 8 9 years of imatinib therapy Median follow-up: 34 months (9-50) Mahon et al. Blood (ASH) 2011; 118: Abstract 603

Definitions of Complete Molecular Response 100% [IRIS baseline] CMR 4.0 ( 4 log reduction; 0.01% IS ) 10% CMR 4.5 ( 4.5 log reduction; 0.0032% IS ) 1% 0.1% 0.01% [IRIS MMR] CMR 5.0 ( 5 log reduction; 0.001% IS ) log reduction = reduction from IRIS baseline, not individual pretreatment levels 0.001% BCR-ABL undetectable International Scale

Loss of MMR as definition of molecular relapse: A-STIM A-STIM study By 24 months: 36% (95% CI: 27-47) At 36 months: 61% (95% CI: 51-73) Rousselot et al. JCO 2014; 32: 424-430. Mahon et al. Blood 2014; 124: abstract 151. Mori et al. Am J Hematol 2015; 90: 910-914.

Main study objective: definition of prognostic markers TKI failure Relapse defined as BCR-ABL > 0.1% (loss of MMR) on the IS at one time point Patients with prior TKI failure were excluded

All pts but 1 who lost MMR restarted 2G-TKI treatment and regained MMR after a median time of 3 months (1-8). Molecular Relapse free survival 200 interim patients overtime, loss MMR=89 Relapses within 6 months, n=77 At 6 months : 63 % (95% CI : 55% - 69%) At 12 months: 56 % (95% CI : 49 % - 63 %) At 18 months : 55 % (95% CI : 47 % - 61 %) 63% remained without relapse the first 6 mo

Interim Analysis of The EURO-SKI study Relapses within 6 months, n=77 Relapses after 6 months, n=12 Among the 89 pts who lost MMR 76 regained MMR and 70 returned to MR 4 1 lost CHR but regained MR 4 15 lost CCyR defined presumably by IS> 1%* 13 regained MMR and 11 regained MR 4 *3 checked by cytogenetic evaluation

Time is a great healer Impact of median duration of MR 4 and of TKI treatment on molecular relapse at 6 months No loss of MMR n = 123 / Loss of MMR n = 77 Median n Relapses (n) Relapses (%) TKI duration < 8y 114 54 47 p=0.0030* TKI duration > 8y 86 23 27 MR 4 duration < 5y 108 49 45 MR 4 duration > 5y 92 28 30 p=0.0305* *Chi2 test

Analysis of The EURO-SKI studyprognostic modelling (n=448, imatinib) Univariate analysis showed no significant association between molecular relapse-free survival at 6 months and age, gender, depth of molecular response (MR4.5 vs not in MR4.5) or risk score (Sokal, EUTOS or ELTS) Treatment duration with Imatinib and MR4 duration were significantly correlated with MMR status at 6 months Odds ratio for the treatment duration was 1.16, meaning that one additional year of imatinib treatment increases the odds to stay in MMR at 6 months by 16% EURO-SKI; Richter et al, EHA meeting, 2016 S145

Impact of different MR levels on outcome No significant difference was observed for relapse according to depth of molecular response at discontinuation (MR 4 vs. MR 4.5 vs. MR 5 ) n Relapses (n) Relapses (%) MR 4 74 37 49 MR 4.5 79 31 39 MR 5 44 17 39 Total 197 85

Adverse Events: TKI withdrawal syndrome 222 AEs in 98 patients were reported 57 AEs in 31 patients were related to treatment stop, no grade 4 n=200 Patients Grade 1-4 n Patients Grade 3 n AEs Grade 1-4 n AEs Grade 3 n Musculoskeletal pain, joint pain, arthralgia Other (sweating, skin disorders, folliculitis, depressive episodes, fatigue urticaria, weight loss) 23 3 39 6 8 0 18 3 Musculoskeletal pain in CML patients after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome? J. Richter et al. J Clin Oncol. 2014 Sep 1;32(25):2821-3. Tyrosine kinase inhibitor withdrawal syndrome: a matter of c-kit? Response to Richter et al. Ph. Rousselot et al.

DESTINY De- Escalation and Stopping Treatment of Imatinib, Nilotinib or sprycel in chronic myeloid leukaemia. A trial of de-escalation and stopping treatment in chronic myeloid leukaemia patients with excellent responses to tyrosine kinase inhibitor therapy. N=174 Minimum of 3 years: Halve dose if MMR for 1 year How much is enough? Minimum of 4 years: Stop if remain in MMR Primary endpoint: MR 3 (MMR) at 3 years Secondary: sustained MR 3 CMR on reduced dose/stop (no bone marrows) EFS, PFS, OS Health Economics, QoL

DESTINY: efficacy During the de-escalation phase (i.e. until 12 months): 12 molecular relapses (loss of MR3 on 2 consecutive samples) have occurred between the second and twelfth month of de-escalation. Cohort Total no. of patients No. of evaluable patients * No. of relapsed patients % of evaluable patients who relapsed after 12 months at half dose 90% Confidence Interval MMR 49 48 9 18.8 % 9.5-28.0 % MR4 125 121 3 2.5 % 0.2 4.8 % *Subtracting losses to follow-up & complete withdrawals (prior to experiencing any event) from the total. Median (IQR) time to relapse: MR3 but not MR4 at trial entry: 4.4 months (3.2 8.1) MR4 at entry : 8.7 months (8.4 10.7) Musculoskeletal and connective tissue disorders 53 new symptoms have been reported by 36 patients (21%).

DESTINY: REDUCTION OF THERAPY BEFORE COMPLETE WITHAWAL IMPROVES THE CHANCE OF SUCCESSFUL TFR DESTINY EURO-SKI 24 month RFS of 77% appears better than in any comparable study to date RFS remains unrelated to age, gender, performance status or prior TKI ( IM vs 2G-TKI) Clark et al, EHA 2017

STOP 2G-TKI: study design CP-CML TKI therapy 3 years 2G-TKI frontline or after imatinib intolerance or resistance D1 M12 M24 M36 M48 M60 CMR4.5 24 months STOP 2G-TKI Year 1 Year 2 Year 3-5 RQ-PCR monthly RQ-PCR Every 2-3 months RQ-PCR Every 3-6 months Primary endpoint: Treatment free survival (TFS) without loss of MMR Molecular relapse: loss of MMR Loss of MMR triggered treatment resumption *Molecular monitoring performed in local laboratories filling international standardization requirements. *20 000 copies of ABL at least.

STOP 2G-TKI 1L n=8 2L n=40 3L n=12 30 nilotinib/30 dasatinib TFR at 12 mo: 63% TFR at 24 mo: 53% Rea et al. Blood 2017; 129: 846-854

Second TKI Discontinuation in CML Patients That Failed First Discontinuation and Subsequently Regained Deep Molecular Response after TKI Re-Challenge 44% TFR at 21.5 mo N=67 Second TKI predominantly imatinib (73%) Median Rx time 31 months of further therapy before second stop Pagliardini T et al, ASH 2016a

Following loss of UMRD In nearly all cases, patients have responded to TKI Majority regain UMRD in 6 mo

Recommendations Stop TKI in context of clinical trial

Criteria for stopping TKI (adapted from NCCN) CP CML-only TKI treatment for at least 3 years Known and quantifiable BCR-ABL1 transcript CMR 4 ( >0.01% IS) for 2 years, 4 tests, 3 months apart No resistance Reliable qpcr test, sensitivity of detection of >4.5 logs, on IS, and results provided in 2 weeks Monthly molecular monitoring for first 6 months, bi-monthly month 7-24, 3 monthly therafter Review in CML specialist centre to discuss appropriateness Prompt resumption of TKI on loss of MMR; monthly PCR for 6 months and then 3 monthly; mutation testing if no MMR in 6 months

Acknowledgements Jamshid Khorashad David Ross Delphine Rea Jane Apperley Steve O Brien Richard Clark Saussane Sausselle Tim Hughes Simone Claudiani George Nesr Haematology department